Author

Helen McShane

The Jenner Institute, University of Oxford - Cited by 17,663 - TB vaccines - immunology - HIV

Biography

Prof. Helen McShane is a Wellcome Trust Senior Clinical Research Fellow and Professor of Vaccinology at the University of Oxford. She is also a consultant HIV physician. Since 2001, she has led a research group focussed on mycobacterial immunity and the development of new vaccines for tuberculosis. Her research programme involves design of candidate vaccines against TB, testing in various preclinical models, and extensive clinical testing through first-in-man clinical trials to field efficacy trials. MVA85A, one of the vaccines she developed, was the first subunit vaccine to undergo field efficacy testing since BCG. 
Title
Cited by
Year
COVID-19 vaccine hesitancy in the UK: the Oxford coronavirus explanations, attitudes, and narratives survey (Oceans) II
D Freeman, BS Loe, A Chadwick, C Vaccari, F Waite, L Rosebrock, ...Psychological medicine 52 (14), 3127-3141, 2022202
617
2022
Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study
RA Evans, H McAuley, EM Harrison, A Shikotra, A Singapuri, M Sereno, ...The Lancet Respiratory Medicine 9 (11), 1275-1287, 2021202
318
2021
Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults
B Killingley, AJ Mann, M Kalinova, A Boyers, N Goonawardane, J Zhou, ...Nature Medicine 28 (5), 1031-1041, 2022202
232
2022
Effects of different types of written vaccination information on COVID-19 vaccine hesitancy in the UK (OCEANS-III): a single-blind, parallel-group, randomised controlled trial
D Freeman, BS Loe, LM Yu, J Freeman, A Chadwick, C Vaccari, ...The Lancet Public Health 6 (6), e416-e427, 2021202
204
2021
Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study
RA Evans, OC Leavy, M Richardson, O Elneima, HJC McAuley, ...The Lancet Respiratory Medicine 10 (8), 761-775, 2022202
158
2022
Online social endorsement and Covid-19 vaccine hesitancy in the United Kingdom
A Chadwick, J Kaiser, C Vaccari, D Freeman, S Lambe, BS Loe, ...Social media+ society 7 (2), 20563051211008817, 2021202
112
2021
Injection fears and COVID-19 vaccine hesitancy
D Freeman, S Lambe, LM Yu, J Freeman, A Chadwick, C Vaccari, F Waite, ...Psychological medicine 53 (4), 1185-1195, 2023202
86
2023
SARS-CoV-2 human challenge studies—establishing the model during an evolving pandemic
G Rapeport, E Smith, A Gilbert, A Catchpole, H McShane, C ChiuNew England Journal of Medicine 385 (11), 961-964, 2021202
36
2021
Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive …
BA Fisher, T Veenith, D Slade, C Gaskell, M Rowland, T Whitehouse, ...The Lancet Respiratory Medicine 10 (3), 255-266, 2022202
29
2022
Local pulmonary immunological biomarkers in tuberculosis
H Morrison, H McShaneFrontiers in Immunology 12, 640916, 212
20
2021
SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination
F Liew, S Talwar, A Cross, BJ Willett, S Scott, N Logan, MK Siggins, ...EBioMedicine 87, 2023202
15
2023
Lessons from the pandemic on the value of research infrastructure
LSJ Roope, P Candio, V Kiparoglou, H McShane, R Duch, PM ClarkeHealth Research Policy and Systems 19 (1), 1-4, 2021202
12
2021
Tuberculosis vaccines in the era of Covid-19–what is taking us so long?
HM Dockrell, H McShaneEBioMedicine 79, 2022202
11
2022
Distinct blood transcriptomic signature of treatment in latent tuberculosis infected individuals at risk of developing active disease
JG Burel, A Singhania, P Dubelko, J Muller, R Tanner, E Parizotto, ...Tuberculosis 131, 102127, 2021202
11
2021
Influence of aerosol delivered BCG vaccination on immunological and disease parameters following SARS-CoV-2 challenge in rhesus macaques
AD White, L Sibley, C Sarfas, AL Morrison, K Bewley, C Churchward, ...Frontiers in immunology 12, 801799, 2022202
10
2022
Induction of functional specific antibodies, IgG-secreting plasmablasts and memory B cells following BCG vaccination
J Bitencourt, MP Peralta-Álvarez, M Wilkie, A Jacobs, D Wright, ...Frontiers in immunology 12, 78207, 2022202
9
2022
Rapid research response to the COVID-19 pandemic: perspectives from a National Institute for Health Biomedical Research Centre
LR Henderson, H McShane, V KiparoglouHealth Research Policy and Systems 20 (1), 24, 2022202
8
2022
Namilumab or infliximab compared to standard of care in hospitalised patients with COVID-19 (CATALYST): a phase 2 randomised adaptive trial
BA Fisher, T Veenith, D Slade, C Gaskell, M Rowland, T Whitehouse, ...medRxiv, 2021.0. 02.21258204, 2021202
6
2021
Phase I Trial Evaluating the Safety and Immunogenicity of Candidate TB Vaccine MVA85A, Delivered by Aerosol to Healthy M.tb-Infected Adults
M Riste, JL Marshall, I Satti, SA Harris, M Wilkie, R Lopez Ramon, ...Vaccines 9 (4), 39, 2021202
6
2021
Equity for excellence in academic institutions: a manifesto for change
L Wedekind, A Noé, J Mokaya, C Tamandjou, M Kapulu, A Ruecker, ...Wellcome Open Research , 2021202
6
2021

Referred From: https://scholar.google.com/citations?hl=en&user=EfZZOpkAAAAJ

Cited by
Citations 17663
h-index 70
i10-index 174
Recommended Journals
Open Access Journals